EN | RU
EN | RU

Help Support

Back

First rituximab biosimilar approved by FDA in market for RA treatment

First rituximab biosimilar approved by FDA in market for RA treatment First rituximab biosimilar approved by FDA in market for RA treatment
First rituximab biosimilar approved by FDA in market for RA treatment First rituximab biosimilar approved by FDA in market for RA treatment

What's new?

Pioneering rituximab biosimilar, the very first is now available for the treatment of RA.

A new FDA approved rituximab biosimilar has been launched in the US for its use in rheumatoid arthritis (RA) therapeutic option in combination with methotrexate. It has been found effective in adults with moderate to severe active RA who was otherwise ineffective to one or more tumor necrosis factor antagonist treatments. 

The adults with granulomatosis with polyangiitis and microscopic polyangiitis could also benefit from this biosimilar, if used in combination with glucocorticoids. Beside these indications, it has been approved in 2019 for Non-Hodgkin lymphoma, chronic lymphocytic leukemia.

According to its manufacturing company, the list price for this biosimilar will be 10% lesser as compared to the reference product. 

Source:

Truxima

Article:

Rituximab Biosimilar Truxima Now Available for Rheumatoid Arthritis

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: